Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT

Sagimet Biosciences Inc. - Series A — Sagimet Biosciences — Investor Presentation (November 2026)

33 slides from Sagimet Biosciences Inc. - Series A's investor presentation, Nov 12, 2026

  1. Slide 1: Targeting Metabolic Dysfunction with Novel Therapeutics

    Exhibit 99.2 Targeting Metabolic Dysfunction with Novel Therapeutics November 2026

  2. Slide 2: Forward-Looking Statements and Disclaimer

    Forward-Looking Statements and Disclaimer This presentation contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this document, other than statements of histori

  3. Slide 3: Leadership Team with Proven Development and Commercialization Experience

    Leadership Team with Proven Development and Commercialization Experience Dave Happel President & CEO Elizabeth Rozek Chief Legal & Administrative Officer >20 years of experience in executive leadership in biotech >20 years of legal experience including executive leadership and pharma of legal, IP an

  4. Slide 4: Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation

    Sagimet at a Glance: Differentiated Dermatology Assets with Clinical Validation • Our lead molecule, denifanstat, is a novel fatty acid synthase (FASN) inhibitor with a differentiated Unique MOA: FASN Inhibition method of action with the potential to target multiple underserved diseases • Strong cli

  5. Slide 5: Strong IP, Cash Position, and Collaboration Potential

    Strong IP, Cash Position, and Collaboration Potential • Successful outcome of Phase 2b clinical trial in MASH (metabolic dysfunction-associated steatohepatitis); met both primary endpoints with significant reduction in fibrosis • Pre-clinical data demonstrated synergistic effect of combination of FA

  6. Slide 6: Development Pipeline: Multiple Indications and Clinical Milestones

    Development Pipeline: Multiple Indications and Clinical Milestones Stage of Development Therapeutic Indication Milestone / Program Updates Area Preclinical Phase 1 Phase 2 Phase 3 First patient dosed in AURORA Phase 3 clinical trial in Denifanstat Oct 2026 Phase 1 FIH clinical trial initiated in Jun

  7. Slide 7: Significant U.S. Acne Market Potential for Denifanstat

    Significant U.S. Acne Market Potential for Denifanstat

  8. Slide 8: Significant U.S. Acne Market Opportunity for Denifanstat

    Significant U.S. Acne Market Opportunity for Denifanstat Novel MOA Supports Significant Market Potential Large U.S. Acne Market Unmet Need with Current Denifanstat Has Potential to Capture Treatments Significant Market Share • 50 million people suffer from acne in • Current topical treatments have •

  9. Slide 9: Acne Treatment Algorithm

    Acne Treatment Algorithm Per the Current AAD Acne Guidelines, Disease Management Involves Flare and Prevention Intervention Moderate to Severe Mild Acne (~38M*) Cystic Acne (~2M*) Acne (~10M*) Treatment includes Treatment approach Cystic patients are topical agents used as adds oral products on gene

  10. Slide 10: U.S. Acne Market Landscape

    U.S. Acne Market Landscape 33.7M Annual Prescriptions for Acne in 2025, Including 12.6M for Oral Treatments Acne Prescriptions by delivery, 2025 (in M) Prescriptions by category, 2025 (in M) Antibiotics 8.0 4.0 12.0 Retinoids 8.8 2.3 11.2 33.7M Anti-androgens 0.4 6.3 6.7 Topical Combo/ 3.9 3.9 Other

  11. Slide 11: FASN Inhibition Offers Differentiated MOA in Acne

    FASN Inhibition Offers Differentiated MOA in Acne

  12. Slide 12: Potential Role of FASN Inhibitors in the Pathogenesis of Acne

    Potential Role of FASN Inhibitors in the Pathogenesis of Acne FASN 1 4 key drivers of acne : 2 • Increased sebum in sebaceous glands (80% of lipids produced through DNL) Palmitate / sapienic acid • Abnormal or excessive follicular hyper-keratinization • Accelerated bacterial growth (C. acnes) Lipid

  13. Slide 13: Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne

    Pharmacodynamic Data Support Mechanism of Action of Denifanstat in Acne In multiple Phase 1 clinical trials, denifanstat Phase 1 oncology clinical trial 1-3 1,2 demonstrated a decrease in DNL sebum lipids Sebutape® assessment of cutaneous sebum lipids • Demonstrated a >90% reduction in sebum lipids

  14. Slide 14: Denifanstat's Clinical Data in Acne

    Denifanstat’s Clinical Data in Acne

  15. Slide 15: Design of Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304)

    Design of Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304) Clinical Trials Conducted in China by Sagimet’s License Partner, Ascletis Phase 3 Phase 3 1 2 Double blind clinical trial Open label extension (OLE) Denifanstat Phase 3 in Acne ASC40-303 ASC40-304 Denifanstat (50mg) • Moderate to sever

  16. Slide 16: ASC40-303 Baseline Characteristics

    ASC40-303 Baseline Characteristics Baseline Characteristics 50mg Denifanstat Placebo Total (n=240) (n=240) (n=480) Age, years, mean (SD) 22.7 (4.0) 22.5 (3.5) 22.6 (3.8) Male, n (%) 79 (32.9) 71 (29.6) 150 (31.3) Female, n (%) 161 (67.1) 169 (70.4) 330 (68.8) IGA=3 (moderate), n (%) 206 (85.8) 206 (

  17. Slide 17: Denifanstat Met All Primary and Secondary Endpoints in ASC40-303

    Denifanstat Met All Primary and Secondary Endpoints in Acne Phase 3 Clinical Trial (ASC40-303) 50mg Denifanstat Placebo 50mg Denifanstat 1 Efficacy endpoints p value (n=240) (n=240) (placebo adjusted) 2 % Treatment success (IGA) (primary endpoint) 33.2 14.6 18.6 <0.0001 % Change in total lesion coun

  18. Slide 18: Statistically Significant Effect on Skin Lesions Starting Week 4

    In ASC40-303, Denifanstat Showed Statistically Significant Effect on Skin Lesions Starting Week 4 Percent Change in Total, Inflammatory and Non-inflammatory Lesion Count Over Time ** *** *** *** ** *** *** *** *** Ascletis data on file. Note: * p<0.01, ** p<0.01, *** p<0.001 November 2026 18

  19. Slide 19: ASC40-303 Safety Data

    ASC40-303 Safety Data Denifanstat 50mg Was Generally Well-Tolerated During the 12-Week Clinical Trial Adverse events (AEs): • AE incidence rates were comparable between denifanstat and placebo • Only two categories of treatment related AEs had an incidence rate of 5% or more: • Dry eye (investigator

  20. Slide 20: Baseline Characteristics of ASC40-304 Extension Cohorts

    Baseline Characteristics of ASC40-304 Extension Cohorts at ASC40-303 Baseline Baseline Characteristics of OLE Cohorts Consistent With Overall Study Population Baseline Characteristics Denifanstat/Denifanstat Placebo/Denifanstat ASC40-303 Total Baseline (n=116) (n=124) (n=480) Age, years, mean (SD) 2

  21. Slide 21: ASC40-304 Safety Data

    ASC40-304 Safety Data Denifanstat Generally Well-Tolerated in the OLE Clinical Trial Adverse events (AEs): • All denifanstat-related AEs were mild or moderate; no denifanstat-related Grade 3 or 4 AEs • Only two categories of treatment related AEs had an incidence of 5% or more in denifanstat-treated

  22. Slide 22: Further Improvement in IGA Success During the OLE

    During the OLE (ASC40-304), Patients Showed Further Improvement in IGA Success Compared to ASC40-303 Baseline % Patients with IGA ≥ 3 at ASC40-303 Baseline Reaching IGA of 0 or 1 during OLE ASC40-303 & 304 ASC40-303 Ascletis data on file. Week 52/ET (“Early Termination”) = patients who completed the

  23. Slide 23: Further Reduction in Total Lesion Counts During the OLE

    During the OLE (ASC40-304), Patients Showed Further Reduction in Total Lesion Counts (TLC) Compared to ASC40-303 Baseline TLC Mean % Change in TLC From ASC40-303 Baseline in OLE Patients ASC40-303 & 304 ASC40-303 Total skin lesion counts reduced by approximately 75% compared to ASC40-303 baseline fo

  24. Slide 24: Further Reduction in Inflammatory Lesion Counts During the OLE

    During the OLE (ASC40-304), Patients Showed Further Reduction in Inflammatory Lesion Counts (ILC) Compared to ASC40-303 Baseline ILC Mean % Change From ASC40-303 Baseline in OLE Patients ASC40-303 & 304 ASC40-303 Inflammatory skin lesion counts reduced by approximately 80% compared to ASC40-303 base

  25. Slide 25: Further Reduction in Non-Inflammatory Lesion Counts During the OLE

    During the OLE (ASC40-304), Patients Showed Further Reduction in Non- Inflammatory Lesion Counts (NILC) Compared to ASC40-303 Baseline NILC Mean % Change From ASC-303 Baseline in OLE Patients ASC40-303 ASC40-303 & 304 Ascletis data on file. Week 52/ET (“Early Termination”) = patients who completed t

  26. Slide 26: Improved Efficacy Through Week 24-36, Sustained Through Week 52

    During the OLE (ASC40-304), Patients Showed Improved Efficacy Through Week 24-36, Which Was Sustained Through Week 52 Percent Change in Total, Inflammatory and Non-inflammatory Lesion Count Over Time Total Lesion Count Non-Inflammatory Lesion Count Inflammatory Lesion Count -27.1% -36.4% -46.3% -65.

  27. Slide 27: Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304) Summary

    Acne Phase 3 Clinical Trials (ASC40-303 and ASC40-304) Summary • In ASC40-303, patients dosed with denifanstat 50mg over 12 weeks demonstrated statistically significant improvement in: • Investigator Global Assessment (IGA)-scores • Inflammatory, non-inflammatory, and total lesion counts • In ASC40-

  28. Slide 28: Sagimet's Development Programs

    Sagimet’s Development Programs

  29. Slide 29: AURORA Phase 3 Clinical Trial for Denifanstat in Acne

    AURORA Phase 3 Clinical Trial for Denifanstat in Acne AURORA Phase 3 acne clinical trial 12 week 40 week design Double blind clinical trial Open label extension • Moderate to severe acne Denifanstat (50mg) • Multi-center placebo controlled Denifanstat (50mg) N= 533 Screening • 2:1 randomization N~53

  30. Slide 30: FASN Inhibitor TVB-3567 FIH Ongoing Phase 1 Clinical Trial

    FASN Inhibitor TVB-3567 FIH Ongoing Phase 1 Clinical Trial Initiated in June 2025 A double-blind, randomized, placebo-controlled clinical trial to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of TVB-3567 in healthy participants with or

  31. Slide 31: Potential Clinical Development Program for TVB-3567 in Acne

    Potential Clinical Development Program for TVB-3567 in Acne Phase 1 clinical trial initiated in June 2025 Goal: Initiate Phase 2 clinical trial in 2026 • Phase 1 first-in-human pharmacokinetic (PK) clinical trial of TVB-3567 in healthy volunteers • PK and pharmacodynamics (PD) evaluation to confirm

  32. Slide 32: Denifanstat for Treatment of MASH

    Denifanstat for Treatment of MASH Clinical and Pre-Clinical Data Demonstrate Denifanstat’s Potential to Treat MASH (Metabolic Dysfunction- Associated Steatohepatitis) • MASH F2-F3: • Denifanstat met both primary endpoints in Phase 2b clinical trial, with significant reduction in fibrosis and was gen

  33. Slide 33: FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne

    FASN Inhibition – Significant Opportunity for a Novel Treatment for Acne • Acne market is significant (~50m people in the US) and aligned to those patients most likely to be prescribed an oral FASN inhibitor • Oral FASN inhibitors offer a novel mechanism of action for the potential treatment of mode

Sagimet Biosciences — Investor Presentation (November 2026) on 6ix